Dosing
Fixed-dose Combination Articles

Once-Daily Lopinavir/ritonavir (Kaletra) and Nevirapine (Viramune) Demonstrate Suboptimal Efficacy in Some Patients  - 3/16/07

Bioequivalence of Pilot 100 mg Tablet Formulations of Ritonavir to the Marketed Soft Gel Capsule  - 3/09/07

Stavudine, Lamivudine and Nevirapine Is Maintained Longer than Other First-line Regimens in a Large Asian Cohort  1/19/07

Once-daily Boosted Fosamprenavir or Atazanavir in Treatment-naive Patients: The ALERT Study   10/06/06

Efficacy and Impact on Lipids of Reduced Lopinavir/ritonavir Dosing   10/03/06

Lopinavir/ritonavir Once Daily May Be a Suitable Regimen for Antiretroviral-naive Children - 4/14/06

Simple Regimens Are Highly Effective in Developing World - 2/28/06

First Report of Development of Resistance to Boosted Fosamprenavir in an ART-naïve Subject: Virologic and Clinical Outcome. P Sax and others.- 12/18/05

Week 48 Analysis of Once-Daily (QD) Trizivir (TZV) and Tenofovir DF (TDF) in Antiretroviral Naïve Subjects (COL40263). C Cohen and others. - 12/18/05

Differences in Treatment Compliance Between Lopinavir/ritonavir (LPV/r) Given Once (QD) Versus Twice (BID) Daily Do Not Affect Virologic or Immunologic Outcomes. R Rhode and others. - 12/18/05

Once Daily Regimen of Saquinavir, Ritonavir, Didanosine, and Lamivudine in HIV Patients on Standard Tuberculosis Therapy - 11/02/05

Report on the XIV International HIV Drug Resistance Workshop: Parts 1-3 - 7/06/05

The Pharmacology of Nucleoside and Nucleotide Reverse Transcriptase Inhibitors: Implications for Once-Daily Dosing - 7/06/05

Once Daily Abacavir in Place of Twice Daily Dosing - 6/29/05

Drug Concentration Control Provides No Apparent Help in HIV Salvage Therapy - 6/08/05

Roche Gains European Approval for More Potent Formulation of Saquinavir - 6/01/05

Adherence Is Better after Switching from Twice-daily to Once-daily Therapy for HIV: Treatment Simplification Using Stavudine Prolonged-release Capsules - 5/25/05

FDA Approves Lopinavir/Ritonavir 800/200mg Once Daily for Treatment of HIV in Therapy-naïve Adults - 5/04/05

48-week Efficacy of Once-daily Saquinavir Soft-gel/Ritonavir in Patients with Undetectable Viral Load after 3 Years of Antiretroviral Therapy - 4/06/05

Abacavir Once Daily Is Not Inferior to Abacavir Twice-daily Dosing Schedule When  Combined with Lamivudine and Efavirenz Over 48 Weeks - 3/18/05

FDA Grants Fast-Track Review Status to PA-457, First in a New Class of Anti-HIV Drugs - 2/14/05

Indinavir/Ritonavir-based Therapy in Treatment-naive Patients: Comparison of 800/100 mg and 400/100 mg Twice Daily - 2/09/05

Weight-related Differences in the Pharmacokinetics of Abacavir in HIV Patients 2/04/05

Single-dose Safety and Pharmacokinetics of Amprenavir in HIV-infected Children - 1/26/05

A Study of Emtricitabine and Lamivudine in Stably Suppressed Patients with HIV - 1/14/05

Bristol-Myers Squibb and Gilead Sciences Establish Joint Venture to Develop a Once Daily Fixed Dose Combination of Three Anti-HIV Drugs - 1/03/05